卵巢高级别浆液性癌的形态学、免疫组织化学和分子特征综述。

Angela Santoro, Giuseppe Angelico, Antonio Travaglino, Frediano Inzani, Saveria Spadola, Angela Pettinato, Manuel Mazzucchelli, Emma Bragantini, Livia Maccio, Gian Franco Zannoni
{"title":"卵巢高级别浆液性癌的形态学、免疫组织化学和分子特征综述。","authors":"Angela Santoro, Giuseppe Angelico, Antonio Travaglino, Frediano Inzani, Saveria Spadola, Angela Pettinato, Manuel Mazzucchelli, Emma Bragantini, Livia Maccio, Gian Franco Zannoni","doi":"10.1016/j.critrevonc.2024.104603","DOIUrl":null,"url":null,"abstract":"<p><p>High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FRα) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104603"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features.\",\"authors\":\"Angela Santoro, Giuseppe Angelico, Antonio Travaglino, Frediano Inzani, Saveria Spadola, Angela Pettinato, Manuel Mazzucchelli, Emma Bragantini, Livia Maccio, Gian Franco Zannoni\",\"doi\":\"10.1016/j.critrevonc.2024.104603\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FRα) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.</p>\",\"PeriodicalId\":93958,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\" \",\"pages\":\"104603\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.critrevonc.2024.104603\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.critrevonc.2024.104603","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

高级别浆液性卵巢癌(HGSOC)是上皮性卵巢癌中最具侵袭性的亚型,也是妇科恶性肿瘤中导致死亡的主要原因。本文旨在全面分析HGSOC的形态学、免疫组织化学和分子特征,突出其发病机制,并确定具有诊断、预后和治疗意义的生物标志物。特别强调肿瘤微环境(TME)和基因组不稳定性在塑造肿瘤行为和治疗脆弱性中的作用。主要进展,如TP53和BRCA突变的鉴定,同源重组修复(HRR)缺陷的分类,以及叶酸受体α (FRα)和PD-L1等生物标志物的临床意义。这些发现为靶向治疗提供了可行的见解,包括免疫检查点抑制剂和PARP抑制剂,它们有望改善HGSOC的预后。这种知识的综合旨在弥合理解HGSOC的多方面生物学的差距,加强临床决策,并促进精确治疗的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
The multiple facets of ovarian high grade serous carcinoma: A review on morphological, immunohistochemical and molecular features.

High-grade serous ovarian carcinoma (HGSOC) is the most aggressive subtype of epithelial ovarian cancer and a leading cause of mortality among gynecologic malignancies. This review aims to comprehensively analyze the morphological, immunohistochemical, and molecular features of HGSOC, highlighting its pathogenesis and identifying biomarkers with diagnostic, prognostic, and therapeutic significance. Special emphasis is placed on the role of tumor microenvironment (TME) and genomic instability in shaping the tumor's behavior and therapeutic vulnerabilities. Key advancements, such as the identification of TP53 and BRCA mutations, the classification of homologous recombination repair (HRR) deficiencies, and the clinical implications of biomarkers like folate receptor alpha (FRα) and PD-L1 are discussed. These findings reveal actionable insights into targeted therapies, including immune checkpoint inhibitors and PARP inhibitors, which hold promise for improving outcomes in HGSOC. This synthesis of knowledge aims to bridge gaps in understanding HGSOC's multifaceted biology, enhance clinical decision-making, and foster the development of precision therapies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: what before chemotherapy? A glimpse into the future. CAR T-cell Therapy Landscape in Pediatric, Adolescent and Young Adult Oncology - A Comprehensive Analysis of Clinical Trials. Harnessing Pseudogenes for Lung Cancer: A Novel Epigenetic Target in Diagnosis, Prognosis and Treatment. Immune Watchdogs: Tissue-Resident Lymphocytes as Key Players in Cancer Defense. Key Considerations for a Prostate Cancer mRNA Vaccine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1